Methylmalonyl-CoA mutase

Methylmalonyl CoA mutase

Rendering based on PDB 2XIJ​.
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols MUT ; MCM
External IDs OMIM: 609058 MGI: 97239 HomoloGene: 20097 GeneCards: MUT Gene
EC number 5.4.99.2
RNA expression pattern
More reference expression data
Orthologs
Species Human Mouse
Entrez 4594 17850
Ensembl ENSG00000146085 ENSMUSG00000023921
UniProt P22033 P16332
RefSeq (mRNA) NM_000255 NM_008650
RefSeq (protein) NP_000246 NP_032676
Location (UCSC) Chr 6:
49.43 – 49.46 Mb		 Chr 17:
40.93 – 40.96 Mb
PubMed search
methylmalonyl-CoA mutase
Identifiers
EC number 5.4.99.2
CAS number 9023-90-9
Databases
IntEnz IntEnz view
BRENDA BRENDA entry
ExPASy NiceZyme view
KEGG KEGG entry
MetaCyc metabolic pathway
PRIAM profile
PDB structures RCSB PDB PDBe PDBsum
Gene Ontology AmiGO / EGO

Methylmalonyl Coenzyme A mutase, also known as MCM is an enzyme that catalyzes the isomerization of methylmalonyl-CoA to succinyl-CoA and it is involved in key metabolic pathways. It requires a vitamin B12-derived prosthetic group, adenosylcobalamin (commonly referred to as AdoCbl), to function.

Methylmalonyl-CoA mutase was first identified in rat liver and sheep kidney in 1955. In its latent form, it is 750 amino acids in length. Upon entry to the mitochondria, the 32 amino acid mitochondrial leader sequence at the N-terminus of the protein is cleaved, forming the fully processed monomer. The monomers then associate into homodimers, and bind AdoCbl (one for each monomer active site) to form the final, active holoenzyme form.[1]

The processing protein, MMAA protein, fills the important role of aiding cofactor loading and exchange.[2][3] MMAA protein favors association with the MCM apoenzyme, and allows for the transfer of the AdoCbl cofactor to the enzyme active site.[3] Furthermore, if the bound AdoCbl accrues oxidative damage during normal functioning, MMAA protein fosters exchange of the damaged cofactor for a new AdoCbl via a GTP-reliant pathway.[2][3]

Methylmalonyl-CoA mutase is expressed in high concentrations in the kidney, in intermediate concentrations in the heart, ovaries, brain, muscle, and liver, and in low concentrations in the spleen.[1] The enzyme can be found all throughout the central nervous system (CNS).[1]

Function

Methylmalonyl-CoA mutase catalyzes the following reaction:

L-methylmalonyl-CoA methylmalonyl-CoA mutase Succinyl-CoA
 
 
  methylmalonyl-CoA mutase

The substrate of methylmalonyl-CoA mutase, methylmalonyl-CoA, is primarily derived from propionyl-CoA, a substance formed from the catabolism and digestion of isoleucine, valine, threonine, methionine, thymine, cholesterol, or odd-chain fatty acids.

The product of the enzyme, succinyl-CoA, is a key molecule of the TCA cycle.

MCM resides in the mitochondria, where a number of substances, including the branched-chain amino acids isoleucine and valine, as well as methionine, threonine, thymine and odd-chain fatty acids, are metabolized via methylmalonate semialdehyde (MMlSA) or propionyl-CoA (Pr-CoA) to a common compound - methylmalonyl-CoA (MMl-CoA).

Human Genetics

The gene encoding for this enzyme in humans is known as MUT,[4] which corresponds to chromosome 6p12-21.2.

Pathology

A deficiency of this enzyme is responsible for an inherited disorder of metabolism, Methylmalonyl-CoA mutase deficiency, which is one of the causes of methylmalonic acidemia (also referred to as methylmalonic aciduria or MMA).

Either mutations to the gene MUT (encodes methylmalonyl-CoA mutase), or MMAA (encodes a chaperone protein of methylmalonyl-CoA mutase, MMAA protein) can lead to methylmalonyl acidemia.[2] Mutations to MUT can be categorized as either MUT0 (demonstrates no activity even in presence of excess AdoCbl), or MUT1 (demonstrates very low activity in presence of excess AdoCbl).[5] Over half of the mutations of MUT are missense mutations[6] while nonsense mutations comprise a significant remaining fraction (approximately 14%)[7]

Common treatment methods for MMA include a liver transplant or a liver and kidney transplant to combat the renal disease of methylmalonic acidemia. However, detrimental neurological effects can continue to plague patients even after a successful operation. It is thought that this is due to the widespread presence of methylmalonyl-CoA mutase throughout the central nervous system. Due to the loss of functionality of the enzyme, substrate levels build up in the CNS. The substrate, L-methylmalonyl-CoA hydrolyzes to form methylmalonate (methylmalonic acid), a neurotoxic dicarboxylic acid that, due to the poor dicarboxylic acid transport capacities of the blood-brain barrier, is effectively trapped within the CNS, leading to neurological debilitation. To combat these effects perioperative anti-catabolic regimes and no diet discontinuation are recommended.[1]

MUT has also been linked to bovine tuberculosis (bTB), a form of tuberculosis that affects mostly livestock and accounts for 10% of human cases.[8] It has been proposed that high MUT expression (thus high methylmalonyl-CoA mutase levels) leads to lower cholesterol levels which increases resistance to bTB and affords an improved response to the BCG vaccine.[8]

The murine model has proven an adequate and accurate way of studying the effects of MMA, and potential treatment methods.[9][10]

Mechanism

MCM's reaction mechanism

The MCM reaction mechanism begins with homolytic cleavage of AdoB12's C-Co(III) bond, the C and Co atoms each acquire one of the electrons that formed the cleaved electron pair bond. The Co ion, therefore, fluctuates between its Co(III) and Co(II) oxidation states [the two states are spectroscopically distinguishable: Co(III) is red and diamagnetic (no unpaired electrons), whereas Co(II) is yellow and paramagnetic (unpaired electrons)]. Hence, the role of coenzyme B-12 in the catalytic process is that of a reversible free radical generator. The C-Co(III) bond is well suited to this function because it is inherently weak (dissociation energy = 109 kJ/mol) and appears to be further weakened through steric interactions with the enzyme. A homolytic cleavage reaction is unusual in biology; most other biological bond cleavage reactions occur via heterolytic cleavage (in which the electron pair forming the cleaved bond is fully acquired by one of the separating atoms).

Methylmalonyl-CoA mutase is a member of the isomerase subfamily of adensylcobalamin-dependent enzymes. Furthermore, it is classified as class I, as it is a ‘DMB-off’/’His-on’ enzyme. This refers to the nature of the AdoCbl cofactor in the active site of methylmalonyl CoA.[11] AdoCbl is composed of a central cobalt-containing Corrin ring, an upper axial ligand (β-axial ligand), and a lower axial ligand (α-axial ligand). Both axial ligands are initially bonded to the central cobalt atom. In methylmalonyl-CoA mutase the β-axial ligand is 5’-deoxy-5’-adenosine and is involved in the free radical chemistry of the reaction. The α-axial ligand is 5,6-dimethylbenzimidazole (DMB) and is involved in organizing the active site to enable Histidine-610 to bond with Co, instead of DMB (the reason for the ‘DMB-off’/’His-on’ notation).[11] The Histidine-610 residue is critical to enzyme functionality. Its binding increases the rate of homolytic β-axial ligand – Co bond breakage by a factor of 1012.[12]

MCM active site. Corrin ring and α-axial ligand (DMB): (yellow), β-axial ligand: (green), substrate/product: (cyan), residues interacting with β-axial ligand: glu370, asn366, gly91, ala139 (blue), residues interacting with substrate: gln197, his244, arg207, tyr89 (red), and his610: (orange).[13] Rendered from PDB 4REQ.[14]

Other important residues of methylmalonyl-CoA mutase include Histidine-244, which acts as a general acid near the substrate and shields the radical species from side reactions involving oxygen,[15] Glutamate-370, whose hydrogen bond with the 2’-OH group of the ribose of the β-axial ligand forces interaction between the β-axial ligand radical species and the substrate,[16] and tyrosine-89 which stabilizes reactive radical intermediates and accounts for the stereo-selectivity of the enzyme.[13][17]

See also

References

  1. 1 2 3 4 Ballhausen D, Mittaz L, Boulat O, Bonafé L, Braissant O (2009). "Evidence for catabolic pathway of propionate metabolism in CNS: expression pattern of methylmalonyl-CoA mutase and propionyl-CoA carboxylase alpha-subunit in developing and adult rat brain". Neuroscience 164 (2): 578–87. doi:10.1016/j.neuroscience.2009.08.028. PMID 19699272.
  2. 1 2 3 Takahashi-Íñiguez T, García-Arellano H, Trujillo-Roldán MA, Flores ME (2011). "Protection and reactivation of human methylmalonyl-CoA mutase by MMAA protein". Biochem. Biophys. Res. Commun. 404 (1): 443–7. doi:10.1016/j.bbrc.2010.11.141. PMID 21138732.
  3. 1 2 3 Froese DS, Kochan G, Muniz JR, Wu X, Gileadi C, Ugochukwu E, Krysztofinska E, Gravel RA, Oppermann U, Yue WW (2010). "Structures of the human GTPase MMAA and vitamin B12-dependent methylmalonyl-CoA mutase and insight into their complex formation". J. Biol. Chem. 285 (49): 38204–13. doi:10.1074/jbc.M110.177717. PMC 2992254. PMID 20876572.
  4. ↑ "Entrez Gene: MUT methylmalonyl Coenzyme A mutase".
  5. ↑ Drennan CL, Matthews RG, Rosenblatt DS, Ledley FD, Fenton WA, Ludwig ML (1996). "Molecular basis for dysfunction of some mutant forms of methylmalonyl-CoA mutase: deductions from the structure of methionine synthase". Proc. Natl. Acad. Sci. U.S.A. 93 (11): 5550–5. doi:10.1073/pnas.93.11.5550. PMC 39284. PMID 8643613.
  6. ↑ Forny P, Froese DS, Suormala T, Yue WW, Baumgartner MR (2014). "Functional characterization and categorization of missense mutations that cause methylmalonyl-CoA mutase (MUT) deficiency". Hum. Mutat. 35 (12): 1449–58. doi:10.1002/humu.22633. PMID 25125334.
  7. ↑ Buck NE, Wood LR, Hamilton NJ, Bennett MJ, Peters HL (2012). "Treatment of a methylmalonyl-CoA mutase stopcodon mutation". Biochem. Biophys. Res. Commun. 427 (4): 753–7. doi:10.1016/j.bbrc.2012.09.133. PMID 23041189.
  8. 1 2 de la Fuente J, Gortazar C, Vicente J, Villar M (2011). "Host expression of methylmalonyl-CoA mutase and tuberculosis: a missing link?". Med. Hypotheses 76 (3): 361–4. doi:10.1016/j.mehy.2010.10.040. PMID 21084167.
  9. ↑ Chandler RJ, Venditti CP (2012). "Pre-clinical efficacy and dosing of an AAV8 vector expressing human methylmalonyl-CoA mutase in a murine model of methylmalonic acidemia (MMA)". Mol. Genet. Metab. 107 (3): 617–9. doi:10.1016/j.ymgme.2012.09.019. PMC 3522145. PMID 23046887.
  10. ↑ Manoli I, Sysol JR, Li L, Houillier P, Garone C, Wang C, Zerfas PM, Cusmano-Ozog K, Young S, Trivedi NS, Cheng J, Sloan JL, Chandler RJ, Abu-Asab M, Tsokos M, Elkahloun AG, Rosen S, Enns GM, Berry GT, Hoffmann V, DiMauro S, Schnermann J, Venditti CP (2013). "Targeting proximal tubule mitochondrial dysfunction attenuates the renal disease of methylmalonic acidemia". Proc. Natl. Acad. Sci. U.S.A. 110 (33): 13552–7. doi:10.1073/pnas.1302764110. PMC 3746875. PMID 23898205.
  11. 1 2 Takahashi-Iñiguez T, García-Hernandez E, Arreguín-Espinosa R, Flores ME (2012). "Role of vitamin B12 on methylmalonyl-CoA mutase activity". J Zhejiang Univ Sci B 13 (6): 423–37. doi:10.1631/jzus.B1100329. PMC 3370288. PMID 22661206.
  12. ↑ Vlasie M, Chowdhury S, Banerjee R (2002). "Importance of the histidine ligand to coenzyme B12 in the reaction catalyzed by methylmalonyl-CoA mutase". J. Biol. Chem. 277 (21): 18523–7. doi:10.1074/jbc.M111809200. PMID 11893736.
  13. 1 2 Mancia F, Smith GA, Evans PR (1999). "Crystal structure of substrate complexes of methylmalonyl-CoA mutase". Biochemistry 38 (25): 7999–8005. doi:10.1021/bi9903852. PMID 10387043.
  14. ↑ Mancia F, Evans PR (1998). "Conformational changes on substrate binding to methylmalonyl CoA mutase and new insights into the free radical mechanism". Structure 6 (6): 711–20. doi:10.1016/s0969-2126(98)00073-2. PMID 9655823.
  15. ↑ Maiti N, Widjaja L, Banerjee R (1999). "Proton transfer from histidine 244 may facilitate the 1,2 rearrangement reaction in coenzyme B(12)-dependent methylmalonyl-CoA mutase". J. Biol. Chem. 274 (46): 32733–7. doi:10.1074/jbc.274.46.32733. PMID 10551831.
  16. ↑ Buckel W, Friedrich P, Golding BT (2012). "Hydrogen bonds guide the short-lived 5'-deoxyadenosyl radical to the place of action". Angew. Chem. Int. Ed. Engl. 51 (40): 9974–6. doi:10.1002/anie.201205299. PMID 22945861.
  17. ↑ Thomä NH, Meier TW, Evans PR, Leadlay PF (1998). "Stabilization of radical intermediates by an active-site tyrosine residue in methylmalonyl-CoA mutase". Biochemistry 37 (41): 14386–93. doi:10.1021/bi981375o. PMID 9772164.

Further reading

External links

This article is issued from Wikipedia - version of the Sunday, February 07, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.